Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Naveglitazar (LY 519818, LY 9818) is a peroxisome proliferator-activated receptor (PPAR) modulator, which has entered phase II clinical trials for the treatment of type 2 diabetes.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Naveglitazar (LY 519818, LY 9818) is a peroxisome proliferator-activated receptor (PPAR) modulator, which has entered phase II clinical trials for the treatment of type 2 diabetes. |
Synonyms | LY 9818, LY-519818, LY519818, LY9818, LY-9818, LY 519818 |
Molecular Weight | 422.47 |
Formula | C25H26O6 |
CAS No. | 476436-68-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Naveglitazar 476436-68-7 LY 9818 LY-519818 LY519818 LY9818 LY-9818 LY 519818 inhibitor inhibit